| Rank |
Status |
Study |
| 1 |
Recruiting
|
Mild Versus Moderate Therapeutic Hypothermia in Out-of-hospital Cardiac Arrest Patients
| Condition: |
Cardiac Arrest |
| Intervention: |
Other: Therapeutic Hypothermia |
| Outcome Measures: |
Number of participants with death or poor neurologic outcome at 6 months; Number of mortality; Number of participants with stroke; Number of participants with bleeding; Length of stay in the unit; Length of stay in the hospital; Number of participants with cardiogenic shock; Number of participants with repeat circulatory arrest requiring cardiopulmonary resuscitation (CPR); Number of participants with seizures; Number of participants with renal failure requiring renal replacement therapy; Number of participants with ventilator associated pneumonia; Number of participants with stent thrombosis; Number of participants discharged home |
|
| 2 |
Unknown †
|
A Preliminary Study on Effect of Omega-3 on Human Sperm
| Condition: |
Oligospermia |
| Intervention: |
Behavioral: commercially available omega-3 fatty acids supplementation |
| Outcome Measures: |
sperm count; sperm Lipid phase transition determination |
|
| 3 |
Recruiting
|
A Post-marketing Study to Monitor the Safety of a MF59-adjuvanted Influenza Vaccine Administered in Korean Subjects Aged 65 Years or Older
| Condition: |
Influenza (Seasonal) |
| Interventions: |
Biological: Novartis MF59-adjuvanted influenza subunit vaccine; Biological: Sandoz Korea MF59-adjuvanted influenza subunit vaccine |
| Outcome Measures: |
Occurrence of solicited local (tenderness, erythema, induration, swelling and pain at the injection site) and systemic reactions (CHILLS, myalgia, arthralgia, headache, sweating, fatigue and fever); Occurrence of unsolicited adverse events; Occurrence of serious adverse events |
|
| 4 |
Recruiting
|
Small-dose Dexmedetomidine Effects on Recovery Profiles of Supratentorial Tumors Patients From General Anesthesia
| Conditions: |
Brain Neoplasms; Surgery |
| Interventions: |
Drug: dexmedetomidine; Drug: normal saline |
| Outcome Measures: |
Hemodynamic impacts; Time of recovery from anesthesia; Cough assessment at tracheal extubation; Degree of sedation; Sedative effectiveness; Test patient's blood pressure during maintenance of anesthesia; Monitor Patient's heart beat during maintenance of anesthesia; Test patient's blood pressure during anesthesia recovery period; Monitor Patient's heart beat during anesthesia recovery period; Observe CHILLS reaction; To measure palinesthesia |
|
| 5 |
Recruiting
|
Open Label Pharmacokinetic-Pharmacogenetic Study on Polymorphisms in the Organic Cation Transporter OCT1
| Conditions: |
Drug Metabolism; Membrane Transport |
| Interventions: |
Drug: Drug application Amitriptyline; Drug: Drug application Desvenlafaxine; Drug: Drug application Sumatriptan; Drug: Drug application Proguanil |
| Outcome Measures: |
Area under the plasma concentration-time curve (AUC) of the investigational drugs; Total clearance, Cmax, Tmax, Mean AbsorptionTime, Alpha and Beta half-lives, Mean Residence Time (MRT) and Volume of distribution of the investigated drugs and their metabolites; Dry mouth, fatigue, nausea, headache, vertigo, tinnitus, CHILLS, anxiety and difficulties to read on Visual Analog Scales.; Sedation on Stanford sedation scale; Pupil diameter, latency, diameter at maximal constriction, amplitude and time for 33% recovery of initial pupil diameter measured by pupillometrie; Genetic variants in OCT1, CYP2C19, CYP2D6 and MAO A |
|
| 6 |
Recruiting
|
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
| Condition: |
Hepatitis C |
| Interventions: |
Biological: Pegylated Interferon Lambda; Drug: Ribasphere; Drug: Daclatasvir |
| Outcome Measures: |
Antiviral activity, as determined by the proportion of non-cirrhotic HCV GT-1b subjects with 12-week sustained virologic response (SVR12), defined as HCV RNA < LLOQ target detected or not detected; Proportion of non-cirrhotic HCV GT-1b subjects with eRVR, defined as HCV RNA < LLOQ target not detected; Proportion of non-cirrhotic HCV GT-1b subjects with treatment-emergent cytopenic abnormalities (anemia as defined by Hb < 10 g/dL, and/or neutropenia as defined by ANC < 750 mm3, and/or thrombocytopenia as defined by platelets < 50,000 mm3) on treatment; Proportion of non-cirrhotic HCV GT-1b subjects with on-treatment (maximum of 12 weeks) interferon-associated flu-like symptoms (pyrexia or CHILLS or pain); Proportion of non-cirrhotic HCV GT-1b subjects with on-treatment (maximum of 12 weeks) interferon-associated musculoskeletal symptoms (arthralgia or myalgia or back pain); Proportion of non-cirrhotic HCV GT-1b subjects with SVR24, defined as HCV RNA < LLOQ target detected or not detected; Frequency of deaths among non-cirrhotic HCV GT-1b subjects through the end of follow-up (maximum of 60 weeks); Frequency of Serious adverse events (SAEs) among non-cirrhotic HCV GT-1b subjects through the end of follow-up (maximum of 60 weeks); Frequency of drug related Adverse events (AEs) among non-cirrhotic HCV GT-1b subjects through the end of treatment (maximum of 12 weeks); Frequency of dose reductions and discontinuations due to AEs among non-cirrhotic HCV GT-1b subjects through the end of treatment (maximum of 12 weeks); Frequency of treatment emergent laboratory abnormalities among non-cirrhotic HCV GT-1b subjects through the end of treatment (maximum of 12 weeks); Proportion of non-cirrhotic HCV GT-1b subjects with interferon-associated constitutional symptoms (fatigue or asthenia) through the end of treatment (maximum of 12 weeks); Proportion of non-cirrhotic HCV GT-1b subjects with interferon-associated neurologic symptoms (headache or dizziness) through the end of treatment (maximum of 12 weeks); Proportion of non-cirrhotic HCV GT-1b subjects with psychiatric symptoms (depression or irritability or insomnia) through the end of treatment (maximum of 12 weeks) |
|
| 7 |
Recruiting
|
Effect of Filarial Infection on Immune Responses in Latent Tuberculosis
| Conditions: |
Tuberculosis; Filariasis |
| Intervention: |
|
| Outcome Measures: |
To compare the immune responses to mycobacterial antigens, including PPD and Mycobacterium tuberculosis culture filtrate protein, in individuals who are LTBI+ Fil- versus those who are LTBI+ Fil+.; To compare immune responses to mycobacterial antigens in LTBI+Fil+ co-infected individuals, before and after treatment for filarialinfection. |
|
| 8 |
Recruiting
|
Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV
| Condition: |
Chronic Hepatitis C Infection |
| Interventions: |
Biological: Pegylated Interferon Lambda-1a; Drug: Daclatasvir (DCV); Drug: Ribasphere (RBV) |
| Outcome Measures: |
Antiviral activity, as determined by the proportion of subjects with SVR12, defined as HCV RNA <LLOQ (25 IU/mL), target detected or target not detected, for each treatment arm; Proportion of subjects with Rapid virologic response (RVR) and Extended Rapid Virologic Response (eRVR), where RVR is defined as <LLOQ target not detected at week 4 and eRVR defined as <LLOQ target not detected at Weeks 4 and 12; Proportion of subjects in each group/duration who achieve HCV RNA <LLOQ target detected or not detected, at end of therapy (SVR24); Proportion of subjects with treatment emergent cytopenic abnormalities (anemia as defined by Hb <10 g/dL, and/or neutropenia as defined by ANC <750 mm3 and/or thrombocytopenia as defined by platelets <50,000 mm3) during the treatment period; Proportion of subjects with the following on treatment IFN-associated symptoms: flu-like symptoms (as defined by pyrexia or CHILLS or pain) and musculoskeletal symptoms (as defined by arthralgia or myalgia or back pain); Frequency of deaths, serious adverse events (SAEs), discontinuations due to Adverse Events (AEs), dose reductions, and severity Grade 3/4 laboratory abnormalities; Absolute and percent change from baseline in the CD4 cell count, lymphocyte cell count, and platelet count |
|
| 9 |
Recruiting
|
Pioglitazone to Treat Opioid Withdrawal Symptoms
| Condition: |
Opioid-Related Disorders |
| Interventions: |
Drug: Pioglitazone; Drug: Placebo |
| Outcome Measures: |
Treatment response, defined as opioid abstinence without severe withdrawal symptoms during the last week of the taper (week 6) and duration in treatment (retention); Overall proportions of opioid-negative urines, proportions of participants needing adjunct medications status at follow-up |
|
| 10 |
Recruiting
|
Treatment and Natural History Study of Lymphomatoid Granulomatosis
| Condition: |
Lymphomatoid Granulomatosis |
| Intervention: |
|
| Outcome Measure: |
|
|
| 11 |
Recruiting
|
Pre-warmed Intravenous Fluids and Monitored Anesthesia Care
| Condition: |
Hypothermia |
| Interventions: |
Other: Pre-warmed fluids; Other: Room temperature fluids |
| Outcome Measures: |
Tympanic membrane temperature; Postoperative chilling and shivering |
|
| 12 |
Recruiting
|
Hyperinvasive Approach in Cardiac Arrest
| Condition: |
Out-of Hospital Cardiac Arrest |
| Interventions: |
Device: Prehospital mechanical compression device, intraarrest cooling and in hospital ECLS (LUCAS, Rhinochill, PLS ECMO); Other: Standard care |
| Outcome Measures: |
Composite endpoint of survival with good neurological outcome (CPC 1-2).; Neurological recovery; Cardiac recovery |
|
| 13 |
Recruiting
|
A Migration and Bone Density Study Comparing Hi-Fatigue Bone Cement and Palacos Bone Cement
| Condition: |
Hip Arthritis |
| Interventions: |
Device: Hi-Fatigue Bone Cement; Device: Palacos Bone Cement |
| Outcome Measure: |
Femoral component migration (roentgen stereo photogrammetric analysis - RSA) |
|
| 14 |
Recruiting
|
Inhaled Nitric Oxide and Inhaled Prostacyclin After Cardiac Surgery for Heart Transplant or LVAD Placement
| Condition: |
Heart Failure |
| Interventions: |
Drug: Nitric Oxide; Drug: Prostacyclin |
| Outcome Measures: |
Pulmonary Hypertension; Right heart dysfunction |
|
